Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Evidence towards the clinical benefits of using directional leads in Deep Brain Stimulation for movement disorders: Consecutive case series
Objective: The objective of the present study was determinate the clinical benefits using directional leads in DBS in two different centers. Background: Deep brain stimulation…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…The Effect of Rasagiline on Motor and Non-Motor Symptoms in Parkinson’s Disease
Objective: In this study, we aimed to evaluate the effect of rasagiline treatment on motor and non-motor symptoms in patients with Parkinson’s disease (PD). Background:…All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare
Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD) receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…A pilot study on the shift from rasagiline to safinamide in fluctuating Parkinson’s disease patients
Objective: Here we investigated the consequences of the shift from rasagiline (RS) to SF in fluctuating PD patients. To this end, we selected patients from…A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…Towards a scoring system to distinguish early parkinsonian variant of multiple system atrophy from Parkinson’s disease
Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD). Background: The differential diagnosis…Is brain perfusion a differentiating factor between Parkinson’s Disease (PD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P)?
Objective: Parkinson’s Disease – Postural Instability Gait Disorder (PD-PIGD) and Progressive Supranuclear Palsy – Parkinsonism Predominant (PSP-P) are entities affected by difficulties in differentiation in…Chromogranin B in cerebrospinal fluid as a novel biomarker for Progressive supranuclear palsy
Objective: To identify the biomarker associated with progressive supranuclear palsy (PSP) for better understanding of a pathophysiology and clinical diagnosis. Background: PSP is one of…
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 149
- Next Page »